In this article
On March 28, 2025, the Food and Drug Administration expanded the use of lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) to include adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have received androgen receptor pathway inhibitor (ARPI) treatment and can wait before starting taxane-based chemotherapy. Patients who have already received treatment for mCRPC should be identified for Pluvicto using Locametz (which contains gallium Ga 68 gozetotide) or another approved PSMA positron emission tomography (PET) product, depending on the PSMA levels in their tumors.
The effectiveness was evaluated in the PSMAfore trial (NCT04689828), a study where 468 patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who had not improved after one androgen receptor pathway inhibitor (ARPI) and were considered by the doctor to delay taxane-based chemotherapy participated. Patients were randomly divided (1:1) to either receive lutetium Lu 177 vipivotide tetraxetan (7.4 GBq [200 mCi] every 6 weeks for 6 doses) or a different type of androgen receptor pathway inhibition (ARPI). Those who experienced disease progression while on the ARPI treatment could switch to the experimental treatment. The primary effectiveness endpoint was radiographic progression-free survival (rPFS) assessed by blinded independent central review, with overall survival (OS) constituting an additional effectiveness endpoint. The median radiographic progression-free survival (rPFS) was 9.3 months (95% confidence interval [CI]: 7, not estimable) for the lutetium Lu 177 vipivotide tetraxetan group and 5.6 months (95% CI: 4, 6) for the ARPI group, with a hazard ratio (HR) of 0.41 (95% CI: 0.29, 0.56); p-value <0.0001. The median overall survival (OS) was 24.5 months (95% CI: 19.5, 28.9) and 23.1 months (95% CI: 19.6, 25.5) in the respective groups (HR 0.91 [95% CI: 0.72, 1.14]; the p-value was not statistically significant). Sixty percent (n=141) of the patients who were randomly chosen to switch to ARPI later started receiving lutetium Lu 177 vipivotide tetraxetan after their disease got worse. Adverse effects were consistent with previous experiences involving lutetium Lu 177 vipivotide tetraxetan, with risks including radiation exposure, reduced bone marrow function, and kidney damage. The recommended dose of lutetium Lu 177 vipivotide tetraxetan is 7.4 GBq (200 mCi) given through an IV every 6 weeks for a total of 6 treatments, or until the disease gets worse or side effects become too severe.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.